Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

BACKGROUND: PF-05280014 was compared with trastuzumab sourced from the European Union (trastuzumab-EU), each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study. Equivalence between treatment groups was demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Rubi K., Tokunaga, Eriko, Adamchuk, Hryhoriy, Vladimirov, Vladimir, Yanez, Eduardo, Lee, Keun Seok, Bondarenko, Igor, Vana, Alicia, Hilton, Fiona, Ishikawa, Tomofumi, Tajima, Kentaro, Lipatov, Oleg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847243/
https://www.ncbi.nlm.nih.gov/pubmed/35133617
http://dx.doi.org/10.1007/s40259-021-00513-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847243/
https://www.ncbi.nlm.nih.gov/pubmed/35133617
http://dx.doi.org/10.1007/s40259-021-00513-7

Ejemplares similares